AL-LAD: Complete LSD-Analogue Pharmacology, Fatality & Safety Monograph

AL-LAD: Complete LSD-Analogue Pharmacology, Fatality & Safety Monograph

Emergency psychedelic toxicity: Collapse, seizure, dangerous agitation/confusion, severe chest pain, very fast/irregular heartbeat, loss of consciousness, or prolonged psychosis after an unknown psychedelic requires urgent medical assessment.

Quick answer

AL-LAD is 6-allyl-6-nor-LSD, a serotonergic lysergamide psychedelic related to—but chemically distinct from—LSD.

Its evidence base is uneven:

• analytical identity: strong;
• preclinical psychedelic activity: strong;
• human-liver metabolism: meaningful;
• commercial/blotter presence: established;
• controlled human pharmacokinetics: absent;
• controlled human safety trials: absent;
• human severe toxicity: sparse, but includes a published fatal ventricular dysrhythmia.

That last point is important because online culture sometimes describes AL-LAD as a gentler or easier LSD analogue. That reputation is not a clinical safety conclusion.

Identity

History

AL-LAD was synthesized in the broader scientific exploration of LSD analogues.

It later appeared in the modern research-chemical/NPS market in:

• powders;
• blotter/paper products.

The 2017 Brandt paper provided the detailed modern analytical characterization that forensic laboratories needed.

Newer derivatives such as 1P-AL-LAD and 1T-AL-LAD show that the market continues to modify the same AL-LAD scaffold.

Pharmacology

AL-LAD produces LSD-like psychedelic behavior in animal models.

The mouse head-twitch response used in lysergamide research is strongly linked to 5-HT2A receptor activation.

AL-LAD was active in this model.

What animal potency does not tell us

It does not establish:

• human dose equivalence to LSD;
• cardiovascular safety;
• psychiatric safety;
• duration;
• a therapeutic index.

A receptor/animal comparison should never be converted into a consumer dosing ratio.

Relationship to LSD

AL-LAD differs from LSD at the N6 substitution.

That apparently small structural change can affect:

• receptor binding;
• metabolism;
• pharmacokinetics;
• subjective profile.

Online claims that AL-LAD is:

• “lighter”;
• “more visual”;
• “less anxious”;
• “shorter”

are community observations, not controlled comparative human evidence.

Fatal ventricular dysrhythmia case

A Clinical Toxicology report described a fatal ventricular dysrhythmia associated with AL-LAD.

The PubMed indexing specifically includes:

• chemically induced long-QT syndrome;
• chemically induced ventricular fibrillation;
• fatal outcome.

This is direct human evidence that severe cardiovascular toxicity can occur in association with AL-LAD.

What one case cannot establish

A single fatal report cannot define:

• incidence;
• a blood concentration threshold;
• who is susceptible;
• whether underlying factors contributed;
• a universal mechanism for every exposure.

It is nevertheless enough to reject the claim that serious cardiotoxicity is impossible.

Cardiovascular risk

Controlled human AL-LAD cardiovascular data are lacking.

The fatal case raises concern for:

• QT-related electrical instability;
• ventricular dysrhythmia.

Potential risk may be influenced by:

• congenital/acquired long-QT vulnerability;
• electrolyte disturbance;
• other QT-prolonging drugs;
• stimulants;
• unknown co-exposures.

No AL-LAD-specific interaction study quantifies those risks.

Acute psychedelic toxicity

Class-level lysergamide concerns include:

• panic/anxiety;
• severe confusion;
• impaired judgment;
• accidents;
• agitation;
• acute psychosis or mania in susceptible individuals.

AL-LAD-specific incidence is not established.

Product identity and blotter evidence

AL-LAD has been analytically identified in modern NPS products.

Blotter appearance does not distinguish:

• AL-LAD;
• LSD;
• 1P-AL-LAD;
• 1T-AL-LAD;
• another lysergamide;
• an entirely different psychedelic.

Chemical confirmation matters.

1P-AL-LAD as a prodrug

A 2022 study found that 1P-AL-LAD converts to AL-LAD in pooled human liver microsomes.

AL-LAD was the most abundant metabolite.

That strongly supports the idea that 1P-AL-LAD may act as an AL-LAD prodrug.

It does not establish a precise human dose conversion.

Newer AL-LAD derivatives

In 2025, Japanese researchers identified 1T-AL-LAD in internet-distributed paper products.

Its biological activity and in-vivo conversion to AL-LAD remain incompletely characterized.

This illustrates an important NPS pattern:

A canonical drug page needs to distinguish AL-LAD itself from newer acylated derivatives that may convert to it.

Metabolism

A 2019 human-liver S9 study examined AL-LAD among nine LSD-based NPS.

Across the lysergamides, common pathways included:

• N-dealkylation;
• hydroxylation;
• combinations of those transformations.

CYP involvement included major roles for:

• CYP1A2;
• CYP3A4.

Those data improve analytical detection but do not constitute a controlled human PK trial.

Pharmacokinetics

No robust controlled human AL-LAD study establishes:

• oral bioavailability;
• time to peak;
• half-life;
• clearance;
• dose-concentration curve;
• concentration-effect relationship.

Community duration estimates are not measured pharmacokinetics.

Drug testing

Routine screening

Routine workplace/emergency panels generally do not specifically test for AL-LAD.

LSD immunoassays cannot be assumed to identify every lysergamide analogue reliably.

Definitive testing

Analytical identification may require:

• LC-MS/MS;
• LC-HRMS/QTOF;
• GC-MS with awareness of lysergamide behavior;
• authentic reference standards;
• parent/metabolite-aware methods.

Interactions

No controlled AL-LAD interaction program exists.

Potential concerns include:

• QT-prolonging drugs;
• stimulants;
• MAO inhibitors;
• serotonergic drugs;
• substances that impair judgment or increase physiologic stress.

No combination should be labeled safe from AL-LAD-specific evidence.

Tolerance

Serotonergic psychedelics can develop rapid pharmacodynamic tolerance.

AL-LAD-specific human tolerance studies are absent.

Cross-tolerance with LSD is biologically plausible but not quantified.

Tolerance should not be treated as a rationale for escalating exposure.

Physical dependence and withdrawal

A classic physical-dependence/withdrawal syndrome is not established for AL-LAD.

There is no evidence-based AL-LAD withdrawal timeline.

This differs from saying the drug is risk-free.

Repeated use can still create harm through:

• psychiatric destabilization;
• impaired behavior;
• cardiovascular vulnerability;
• repeated exposure to uncertain products.

Addiction/use-disorder context

Population-level AL-LAD use-disorder data do not exist.

Classic serotonergic psychedelics generally show lower compulsive reinforcement than powerful stimulants/opioids, but no AL-LAD-specific rate should be invented.

Treatment and support

There is no AL-LAD-specific antidote.

Emergency treatment targets the actual complication:

• cardiac dysrhythmia;
• seizure;
• severe agitation;
• hyperthermia;
• injury;
• psychosis.

Persistent psychiatric or substance-use problems warrant professional care.

Forensic interpretation

A fatal association is not a universal lethal level

The ventricular-dysrhythmia case proves severe human risk can occur.

It does not define a safe/fatal blood concentration cutoff.

Derivatives can complicate interpretation

Detection of AL-LAD may reflect:

• direct AL-LAD exposure;
• metabolism of an acylated derivative such as 1P-AL-LAD.

Scene/product evidence helps distinguish those possibilities.

Special populations

No controlled AL-LAD safety studies establish risk in:

• pregnancy/breastfeeding;
• adolescents;
• older adults;
• congenital/acquired long-QT syndrome;
• cardiovascular disease;
• seizure disorders;
• bipolar or psychotic disorders.

The fatal dysrhythmia case makes cardiac vulnerability particularly important to keep visible.

Legal status — dated October 2, 2026

This review does not identify a U.S. federal schedule listing specifically naming AL-LAD in the primary DEA schedules used here.

That does not mean AL-LAD is lawful in every circumstance.

Federal analogue law, state law, and other national controls may apply depending on jurisdiction and facts.

Exact legal status should be checked by molecule and date.

Myths and misconceptions

“AL-LAD is proven safer than LSD.”
No controlled comparative human safety trial establishes that.

“It cannot cause dangerous heart effects because it is a psychedelic.”
False. A fatal ventricular dysrhythmia case is published.

“1P-AL-LAD and AL-LAD are identical molecules.”
No. 1P-AL-LAD appears to act as a prodrug that can generate AL-LAD.

“Blotter appearance identifies the drug.”
False.

“No withdrawal syndrome means no meaningful harm.”
False.

Evidence ledger

Related evidence

• 1P-LSD
• 1cP-LSD
• 25I-NBOMe
• RC psychedelics evidence hub
• Substance Use, Dependence & Harm Reduction hub

Bottom line

AL-LAD is a chemically and pharmacologically real LSD analogue with far less human safety evidence than its online reputation implies.

The literature supports psychedelic serotonergic activity and explains how newer prodrugs can generate AL-LAD.

It also contains a fatal ventricular dysrhythmia case.

That combination means the right evidence-first description is neither “basically LSD” nor “mystery RC”—it is a well-characterized molecule with a dangerously under-characterized human clinical profile.